The greatest benefit was seen in those who took oral daily low doses of aspirin (75 and 325 mg per day) for five years or more.
Men and women at average risk on an aspirin regimen for a decade could expect relative reductions of 9 percent and 7 percent, respectively, in the rate of cancer, myocardial infarction, or stroke over 15 years, according to the study.
People on an aspirin regimen were at greater risk of bleeding events, however the study found that the cancer reduction benefit outweighed this risk.
The third, a case control study conducted by the Yale School of Public Health, found that the longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer.
Harvey A. Risch, MD, PhD, professor of epidemiology in the Department of Chronic Disease Epidemiology said that men and women who took low-dose aspirin regularly cut their risk nearly in half.
Protection against pancreatic cancer ranged from a 39 percent reduction in risk for those who took low-dose aspirin for six years or less, to 60 percent reduction in risk for those who took low-dose aspirin for more than 10 years.
“There seems to be enough evidence that people who are considering aspirin use to reduce the risk for cardiovascular disease can feel positive that their use might also lower their risk for pancreatic cancer, and quite certainly wouldn’t raise it,” Risch said in a statement.
The Yale study is published in the June 2014 issue of Cancer Epidemiology, Biomarkers & Prevention.
Lynette Summerill is an award-winning writer and water sports enthusiast who lives in San Jose with her husband and two beach loving dogs. In addition to writing about cancer-related issues for EmpowHER, her work has been seen in publications internationally.
Aspirin Fact Sheet. Medline Plus. Accessed 14 August 2014.
History of Aspirin. Accessed 14 Aug. 2012.
NSAIDs May Lower Breast Cancer recurrence Rate in Overweight and Obese Women. AACR press release. Jeremy Moore. 14 Aug. 2014.